N/A N=66 Randomized Single-blind Treatment

Women Veterans' Substance Abuse Treatment

Substance Use Disorders

Bottom Line

View on ClinicalTrials.gov: NCT00734903 ↗

Enrolled (actual)

Serious AEs

16.7%

Results posted

Nov 2018

Primary outcome: Primary: Addiction Severity Index Alcohol Composite — .36; .46; .18; .26 units on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: A Woman's Path to Recovery (Behavioral); 12-Step Facilitation (Behavioral)
Age: Adult, Older Adult · 18+ yrs
Sex: Female
Sponsor: VA Office of Research and Development
Primary completion: Mar 2015

Outcome Measures

Outcome	Result	p-value
PRIMARY Addiction Severity Index Alcohol Composite	.36; .46; .18; .26; .23; .21	—
PRIMARY Addiction Severity Index Drug Composite	.10; .10; .04; .06; .04; .04	—
PRIMARY Brief Addiction Monitor	4.61; 4.48; 1.96; 2.33; 2.33; 1.92	—
SECONDARY Addiction Severity Index Medical Composite Score	.38; .43; .38; .33; .21; .20	—
SECONDARY Addiction Severity Index Employment Composite	.64; .59; .58; .54; .58; .56	—
SECONDARY Addiction Severity Index Psychiatric Composite	.43; .48; .37; .41; .31; .39	—
SECONDARY Addiction Severity Index Family/Social Composite	.20; .29; .14; .22; .23; .30	—
SECONDARY Global Severity Index of the Brief Symptom Inventory	1.55; 1.85; 1.37; 1.34; 1.62; 1.26	—
SECONDARY BASIS-24 Psychosocial Functioning	36.22; 38.05; 33.40; 34.12; 29.80; 29.57	—
SECONDARY Coping Skills Measure	2.25; 2.92; 2.88; 2.95; 2.85; 2.92	—
SECONDARY Alcoholics Anonymous (AA) Intention Measure	5.21; 5.26; 4.90; 4.97; 4.99; 4.97	—

Summary

The purpose of this study is to examine the efficacy of a gender-focused addiction treatment model (A Woman's Path to Recovery) versus a non-gender focused addiction treatment model (12-Step Facilitation) in a sample of women Veterans with substance use disorder.

Eligibility Criteria

Inclusion Criteria

Female Veteran
18-65 years of age
Meet DSM-IV criteria for current SUD with "current" defined as meeting SUD criteria per the DSM-IV and having used a substance within the 90 days prior to intake (to be able to accurately evaluate changes in their substance use from baseline)
Plan to stay in the Boston area for the next 6 months
Have a mailing address and live close enough to come to the hospital once weekly for treatment and/or assessment
Able to complete the Statement of Informed Consent
Willing to participate in all assessments and breathalyzer/urine testing
Willing to provide a release of information such that study staff can contact her other providers as needed regarding any concerns during her participation
Able to obtain medical clearance
Willing to allow us to contact family and/or friends if participant loses contact with us
Literate
Not pregnant or planning to become pregnant

Exclusion Criteria

Any acute medical condition that would interfere with the participant's ability to participate in treatment, or would be of such severity as to affect the individual's psychological functioning (e.g., cancer)
Current bipolar I disorder, schizophrenia or other psychotic disorders or mental retardation or organic mental disorder (determined by screening interview)
Any clinical sign that the client is not sufficiently stable to participate in the treatment, such as client's treatment provider indicating that participation in the treatment would be contraindicated
Dangerousness that would present a threat to other staff or other clients (e.g., history of recent assault)
Client is mandated to treatment
Psychopharmacologic treatment that is planned to change or likely to change substantively over the 3-month active treatment phase (with "substantive" defined as any addition of a new medication or major shift in dosage)

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00734903). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.